INNOVIVA, INC. Costs and Expenses
INNOVIVA, INC. (INVA) reported Costs and Expenses of $321.32 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CostsAndExpenses · last filed 2025-02-26
- INNOVIVA, INC. costs and expenses for the quarter ending 2024-12-31 was $67.11M, a 172.38% increase year-over-year.
- INNOVIVA, INC. costs and expenses for the quarter ending 2024-09-30 was $82.66M.
- INNOVIVA, INC. costs and expenses for the quarter ending 2024-06-30 was $139.18M, a 85.11% increase year-over-year.
- INNOVIVA, INC. costs and expenses for the quarter ending 2024-03-31 was $32.38M, a 8.11% decline year-over-year.
- INNOVIVA, INC. costs and expenses for fiscal 2024 was $321.32M, a 176.13% increase from fiscal 2023.
- INNOVIVA, INC. costs and expenses for fiscal 2023 was $116.36M, a 162.14% increase from fiscal 2022.
- INNOVIVA, INC. costs and expenses for fiscal 2022 was $44.39M.
- INNOVIVA, INC. costs and expenses for fiscal 2021 was -$53.41M.
| Period end | Costs and Expenses 3 month | Costs and Expenses 6 month | Costs and Expenses 9 month | Costs and Expenses 12 month |
|---|---|---|---|---|
| 2024-12-31 | $67.11M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $149.77M derived: sum of 2 quarters · filed 2025-02-26 | $288.95M derived: sum of 3 quarters · filed 2025-02-26 | $321.32M 10-K · filed 2025-02-26 |
| 2024-09-30 | $82.66M 10-Q · filed 2024-11-06 | $221.84M derived: sum of 2 quarters · filed 2024-11-06 | $254.21M 10-Q · filed 2024-11-06 | $278.85M derived: sum of 4 quarters · filed 2025-02-26 |
| 2024-06-30 | $139.18M 10-Q · filed 2024-07-31 | $171.55M 10-Q · filed 2024-07-31 | $196.19M derived: sum of 3 quarters · filed 2025-02-26 | $177.50M derived: sum of 4 quarters · filed 2025-02-26 |
| 2024-03-31 | $32.38M 10-Q · filed 2024-05-08 | $57.01M derived: sum of 2 quarters · filed 2025-02-26 | $38.32M derived: sum of 3 quarters · filed 2025-02-26 | $113.51M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-12-31 | $24.64M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $5.95M derived: sum of 2 quarters · filed 2025-02-26 | $81.13M derived: sum of 3 quarters · filed 2025-02-26 | $116.36M 10-K · filed 2025-02-26 |
| 2023-09-30 | -$18.69M 10-Q · filed 2024-11-06 | $56.49M derived: sum of 2 quarters · filed 2024-11-06 | $91.73M 10-Q · filed 2024-11-06 | $222.22M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $75.19M 10-Q · filed 2024-07-31 | $110.42M 10-Q · filed 2024-07-31 | $240.91M derived: sum of 3 quarters · filed 2025-02-26 | $21.74M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $35.23M 10-Q · filed 2024-05-08 | $165.72M derived: sum of 2 quarters · filed 2025-02-26 | -$53.44M derived: sum of 3 quarters · filed 2025-02-26 | $34.28M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $130.49M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$88.68M derived: sum of 2 quarters · filed 2025-02-26 | -$951.00K derived: sum of 3 quarters · filed 2025-02-26 | $44.39M 10-K · filed 2025-02-26 |
| 2022-09-30 | -$219.17M 10-Q · filed 2023-11-01 | -$131.44M derived: sum of 2 quarters · filed 2023-11-01 | -$86.10M 10-Q · filed 2023-11-01 | |
| 2022-06-30 | $87.72M 10-Q · filed 2023-08-02 | $133.07M 10-Q · filed 2023-08-02 | ||
| 2022-03-31 | $45.34M 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | -$53.41M 10-K/A · filed 2024-03-05 | |||
| 2020-12-31 | -$17.45M 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |